




Searching News Database: vernakalant
HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
HSMN NewsFeed - 26 Sep 2012
Merck Returns Global Marketing and Development Rights for Vernakalant to Cardiome
Merck Returns Global Marketing and Development Rights for Vernakalant to Cardiome
HSMN NewsFeed - 20 Sep 2012
Cardiome Announces Appointment of Jennifer Archibald as Chief Financial Officer
Cardiome Announces Appointment of Jennifer Archibald as Chief Financial Officer
HSMN NewsFeed - 19 May 2009
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
HSMN NewsFeed - 11 Aug 2008
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
HSMN NewsFeed - 11 Dec 2007
FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation